EP3193857A4 - Abirateronacetatformulierung und verfahren zur verwendung - Google Patents

Abirateronacetatformulierung und verfahren zur verwendung Download PDF

Info

Publication number: EP3193857A4
Authority: EP; European Patent Office
Prior art keywords: methods; abiraterone acetate; acetate formulation; formulation; abiraterone
Prior art date: 2014-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP15842591.8A

Other languages

English (en)

French (fr)

Other versions

EP3193857A1 (de

Inventor

Maura Murphy

Paul NEMETH

H. William Bosch

Matthew CALLAHAN

Satya Bhamidipati

Jason Coleman

Christopher Hill

Marck Norret

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sun Pharma Global FZE

Original Assignee

Iceutica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-18

Filing date

2015-09-18

Publication date

2018-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3193857(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-08 Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en

2015-09-18 Application filed by Iceutica Inc filed Critical Iceutica Inc

2017-07-26 Publication of EP3193857A1 publication Critical patent/EP3193857A1/de

2018-04-11 Publication of EP3193857A4 publication Critical patent/EP3193857A4/de

Status Withdrawn legal-status Critical Current

Links

229960004103 abiraterone acetate Drugs 0.000 title 1
UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Epoxy Compounds (AREA)

EP15842591.8A 2014-09-18 2015-09-18 Abirateronacetatformulierung und verfahren zur verwendung Withdrawn EP3193857A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462052294P	2014-09-18	2014-09-18
US14/707,922 US20150246060A1 (en)	2013-03-15	2015-05-08	Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en)	2014-09-18	2015-09-18	Abiraterone acetate formulation and methods of use

Publications (2)

Publication Number	Publication Date
EP3193857A1 EP3193857A1 (de)	2017-07-26
EP3193857A4 true EP3193857A4 (de)	2018-04-11

Family

ID=55533897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15842591.8A Withdrawn EP3193857A4 (de)	2014-09-18	2015-09-18	Abirateronacetatformulierung und verfahren zur verwendung

Country Status (17)

Country	Link
EP (1)	EP3193857A4 (de)
JP (1)	JP2017528457A (de)
KR (2)	KR102617537B1 (de)
CN (1)	CN106687112A (de)
AP (1)	AP2017009804A0 (de)
AU (1)	AU2015317466A1 (de)
BR (1)	BR112017003219A2 (de)
CA (1)	CA2958316A1 (de)
CO (1)	CO2017002472A2 (de)
EA (1)	EA201790650A1 (de)
IL (1)	IL250270B (de)
MD (1)	MD20170048A2 (de)
MX (1)	MX2017003525A (de)
PH (1)	PH12017500239A1 (de)
SG (1)	SG11201701139YA (de)
TN (2)	TN2017000098A1 (de)
WO (1)	WO2016044701A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016162229A1 (en)	2015-04-10	2016-10-13	Capsugel Belgium N.V.	Abiraterone acetate lipid formulations
WO2018187728A1 (en) *	2017-04-07	2018-10-11	Maa Laboratories, Inc.	Methods of improving the solubility and bioavailability of therapeutic agents
WO2020151633A1 (en) *	2019-01-25	2020-07-30	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical compositions
WO2020180942A1 (en)	2019-03-06	2020-09-10	Propella Therapeutics, Inc.	Abiraterone prodrugs
CN110742870B (zh) *	2019-12-04	2021-04-20	武汉大学	醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) *	2020-02-19	2020-05-08	纳兰迦(上海)生物医药科技有限公司	一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) *	2020-03-14	2024-03-29	鲁南制药集团股份有限公司	一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
IL297984A (en) *	2020-05-08	2023-01-01	Janssen Pharmaceutica Nv	Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (de)	2020-07-30	2022-02-02	Galenicum Health S.L.U.	Abirateron zur verwendung in einem verfahren zur behandlung von krebs
US11957696B2 (en)	2021-02-15	2024-04-16	Propella Therapeutics, Inc.	Abiraterone prodrugs
KR20240044329A (ko)	2022-09-28	2024-04-04	한미약품 주식회사	아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013164473A1 (en) *	2012-05-04	2013-11-07	Jagotec Ag	Pharmaceutical composition comprising abiraterone acetate
WO2014009437A1 (en) *	2012-07-11	2014-01-16	Sandoz Ag	Oxidation stability of abiraterone acetate
WO2014145813A1 (en) *	2013-03-15	2014-09-18	Iceutica Inc.	Abiraterone acetate formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6141013B2 (ja) *	2009-04-24	2017-06-07	イシューティカピーティーワイリミテッド	商業的規模での封入ナノ粒子の製造
WO2014009436A1 (en) *	2012-07-11	2014-01-16	Sandoz Ag	Nanosuspension of abiraterone acetate
WO2014009434A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh)	2012-07-27	2012-10-24	海南盛科生命科学研究院	一种含有醋酸阿比特龙的药物组合物及制备工艺

2015
- 2015-09-18 BR BR112017003219A patent/BR112017003219A2/pt not_active IP Right Cessation
- 2015-09-18 AU AU2015317466A patent/AU2015317466A1/en not_active Abandoned
- 2015-09-18 TN TN2017000098A patent/TN2017000098A1/en unknown
- 2015-09-18 WO PCT/US2015/050889 patent/WO2016044701A1/en active Application Filing
- 2015-09-18 MX MX2017003525A patent/MX2017003525A/es unknown
- 2015-09-18 CN CN201580050453.8A patent/CN106687112A/zh active Pending
- 2015-09-18 KR KR1020237001893A patent/KR102617537B1/ko active IP Right Grant
- 2015-09-18 AP AP2017009804A patent/AP2017009804A0/en unknown
- 2015-09-18 JP JP2017512783A patent/JP2017528457A/ja active Pending
- 2015-09-18 SG SG11201701139YA patent/SG11201701139YA/en unknown
- 2015-09-18 KR KR1020177008938A patent/KR102491439B1/ko active IP Right Grant
- 2015-09-18 CA CA2958316A patent/CA2958316A1/en active Pending
- 2015-09-18 EA EA201790650A patent/EA201790650A1/ru unknown
- 2015-09-18 TN TNP/2018/000318A patent/TN2018000318A1/en unknown
- 2015-09-18 EP EP15842591.8A patent/EP3193857A4/de not_active Withdrawn
- 2015-09-18 MD MDA20170048A patent/MD20170048A2/ro not_active Application Discontinuation
2017
- 2017-01-25 IL IL250270A patent/IL250270B/en active IP Right Grant
- 2017-02-09 PH PH12017500239A patent/PH12017500239A1/en unknown
- 2017-03-15 CO CONC2017/0002472A patent/CO2017002472A2/es unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013164473A1 (en) *	2012-05-04	2013-11-07	Jagotec Ag	Pharmaceutical composition comprising abiraterone acetate
WO2014009437A1 (en) *	2012-07-11	2014-01-16	Sandoz Ag	Oxidation stability of abiraterone acetate
WO2014145813A1 (en) *	2013-03-15	2014-09-18	Iceutica Inc.	Abiraterone acetate formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016044701A1 *

Also Published As

Publication number	Publication date
IL250270A0 (en)	2017-03-30
PH12017500239A1 (en)	2017-07-03
IL250270B (en)	2021-02-28
KR20230014878A (ko)	2023-01-30
AU2015317466A1 (en)	2017-02-23
EA201790650A1 (ru)	2017-07-31
AP2017009804A0 (en)	2017-03-31
SG11201701139YA (en)	2017-03-30
JP2017528457A (ja)	2017-09-28
KR20170070025A (ko)	2017-06-21
KR102617537B1 (ko)	2023-12-22
CN106687112A (zh)	2017-05-17
WO2016044701A1 (en)	2016-03-24
KR102491439B1 (ko)	2023-01-25
TN2018000318A1 (en)	2020-01-16
EP3193857A1 (de)	2017-07-26
MD20170048A2 (ro)	2017-08-31
CO2017002472A2 (es)	2017-07-11
TN2017000098A1 (en)	2018-10-19
CA2958316A1 (en)	2016-03-24
MX2017003525A (es)	2017-06-21
BR112017003219A2 (pt)	2017-11-28

Legal Events

Date	Code	Title	Description
2017-06-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-07-26	17P	Request for examination filed	Effective date: 20170418
2017-07-26	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-07-26	AX	Request for extension of the european patent	Extension state: BA ME
2017-12-27	DAV	Request for validation of the european patent (deleted)
2017-12-27	DAX	Request for extension of the european patent (deleted)
2018-04-11	A4	Supplementary search report drawn up and despatched	Effective date: 20180308
2018-04-11	RIC1	Information provided on ipc code assigned before grant	Ipc: C07J 43/00 20060101ALI20180303BHEP Ipc: A61K 31/19 20060101AFI20180303BHEP Ipc: A61K 9/20 20060101ALI20180303BHEP Ipc: A61P 13/08 20060101ALI20180303BHEP Ipc: A61K 31/58 20060101ALI20180303BHEP
2018-06-08	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1241293 Country of ref document: HK
2019-09-18	17Q	First examination report despatched	Effective date: 20190820
2019-10-09	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: SUN PHARMA GLOBAL FZE
2020-06-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-07-29	18D	Application deemed to be withdrawn	Effective date: 20200103
2024-04-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1241293 Country of ref document: HK

Publication	Publication Date	Title
EP3209308A4 (de)	2018-06-27	Aktivierte bifidobakterien und verfahren zur verwendung davon
EP3245291A4 (de)	2018-09-19	Neuartige mikrodystrophine und zugehörige verfahren zur verwendung
EP3319611A4 (de)	2019-03-06	Oxysterole und verfahren zur verwendung davon
IL250270A0 (en)	2017-03-30	Abiraterone acetate formulations and methods of use
EP3377070A4 (de)	2019-07-10	Verbindungen und verfahren zu deren verwendung
EP3319610A4 (de)	2019-03-06	Oxysterole und verfahren zur verwendung davon
EP3319612A4 (de)	2019-03-06	Oxysterole und verfahren zur verwendung davon
EP3157528A4 (de)	2017-12-27	Oxysterole und verfahren zur verwendung davon
EP3092001A4 (de)	2017-08-02	Immunmodulierende zusammensetzungen und verfahren zur verwendung davon
EP3145442A4 (de)	2018-02-14	Intraorale vorrichtung und verfahren zur verwendung
EP3373969A4 (de)	2019-08-14	Glycaninteragierende verbindungen und verfahren zur verwendung
EP3218005A4 (de)	2018-09-12	Glycaninteragierende verbindungen und verfahren zur verwendung
EP3194525A4 (de)	2018-05-23	Stützmittelzusammensetzungen und verfahren zur verwendung
EP3096715A4 (de)	2017-07-05	Bidirektionaler stent und verfahren zur verwendung davon
EP3131534A4 (de)	2017-12-20	Fucoidan-nanogele sowie verfahren zu deren verwendung und herstellung
EP3240576A4 (de)	2018-06-20	Verfahren zur transdifferenzierung und verfahren zur verwendung davon
EP3116511A4 (de)	2017-10-18	Zusammensetzungen von selenoorganischen verbindungen und verfahren zur verwendung davon
EP3310374A4 (de)	2019-02-20	Glutathionformulierung und verfahren zur verwendung
EP3190886A4 (de)	2018-04-25	Zusammensetzung und verfahren zur verwendung davon
EP3389705A4 (de)	2019-08-07	Listerienbasierte immuntherapie und verfahren zur verwendung davon
EP3134088A4 (de)	2017-09-13	Bicyclische pyrazolonverbindungen und verfahren zur verwendung
EP3416665A4 (de)	2019-08-14	Formulierung und verfahren zur verwendung
EP3226955A4 (de)	2018-12-05	Selbstverankernde katheter und verfahren zur verwendung
EP3185872A4 (de)	2018-03-07	Formulierungen von testosteron und behandlungsverfahren damit
EP3137096A4 (de)	2017-11-22	Emailleprodukte und verfahren zur verwendung